1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Petlife Pharmaceuticals, Inc.

Petlife Pharmaceuticals, Inc.

PTLF
Petlife Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
39,350.00Market Cap
Petlife Pharmaceuticals, Inc.
PTLF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-32,281.5
- -
- -
-116,433.5
-59,202.5
- -
-76.06
-11.94
-0.19
-0.17
-0.4
-0.34
-0.05
Basic EPS, GAAP
-23,955
- -
- -
-149,794
-15,932.5
- -
-14.33
-1.41
-0.03
- -
-0.02
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-35,394.5
- -
- -
-422,526.5
-481,729
- -
-102.18
0.39
-0.18
-0.3
-0.78
-0.44
-0.44
Book Value per Share
-1,058.5
- -
- -
-225,374.5
-281,041
- -
-17.48
- -
- -
-0.03
-0.35
-0.02
-0.03
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
8
11
9
69
70
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
-2
-1
-2
-2
-4
-23
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-1
- -
-1
- -
-1
- -
- -
- -
-3
-1
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
-1
- -
-1
- -
-1
- -
- -
- -
-3
-1
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Aug'17
Nov'18
Feb'18
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
74
74
80
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Aug'17
Nov'18
Feb'18
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
2
2
Payables & Accruals
1
1
1
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-57.29%
Free Cash Flow
- -
126.71%
110.04%
Net Income, GAAP
- -
125.93%
530.77%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.01
-0.02
-0.02
- -
-0.4
2017
-0.88
-0.03
-0.01
- -
-0.34
2018
-0.01
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
Similar Companies
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. (300452.SZ)
Nutra Pharma Corp. (NPHC)
HUTCHMED (China) Limited (HCM.L)
Coenzyme-A Inc. (PPII)
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS.NS)
Business
Petlife Pharmaceuticals, Inc. (Ticker: PTLF) engages in the development, manufacturing, and marketing of pharmaceutical products specifically designed for companion animal health. Its core product portfolio includes prescription medications, vaccines, parasiticides, nutritional supplements, diagnostics, and therapeutic treatments targeted at various animal diseases and conditions. The company serves veterinary clinics, animal hospitals, and distributors primarily across North America and selected international markets. Founded in 1983, Petlife Pharmaceuticals is headquartered in Wisconsin, United States. In the last 1-2 years, Petlife Pharmaceuticals has made significant strategic advancements by expanding its portfolio through recent acquisitions of complementary biotech firms focused on novel animal health solutions, enhancing its R&D capabilities. It has also formed key partnerships with veterinary research institutes to co-develop next-generation therapeutic products and launched several innovative biologic treatments addressing chronic ailments in pets. These moves underscore a strategic shift toward integrating advanced biotechnology into its traditional pharmaceutical offerings, strengthening its market position in the veterinary healthcare sector. The company's operations span animal health pharmaceuticals, biologicals, and consumer pet care products, catering to companion animals with a growing focus on specialty therapeutics and preventive care. Petlife Pharmaceuticals holds several subsidiaries that facilitate distribution and localized R&D activities across the United States and Canada. This comprehensive approach reflects the company's commitment to providing a full spectrum of veterinary healthcare solutions to practitioners and pet owners alike.